Literature DB >> 12670900

Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.

Yin Li1, Anthony J Raffo, Lisa Drew, Yuehua Mao, Andy Tran, Daniel P Petrylak, Robert L Fine.   

Abstract

The p53 mutant 143Ala is a human temperature-sensitive mutant with two conformational states. To definitively determine whether the Fas signal transduction pathway and the function of the pathway are dependent on p53 status, we have established stable transfectants of p53 mutant 143Ala in two human cancer cell lines: H1299 (lung cancer line) and PC-3 (prostate cancer line), the native state of which contains null p53 status and can grow at 37 degrees C and 32.5 degrees C. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cell cycle analysis showed inhibition of the growth of cells overexpressing p53 mutant 143Ala in the wild-type p53 form at 32.5 degrees C because of induction of G0/G1 arrest. Transfected cells had increased protein expression of p21, Fas, and MDM2 at the wild-type p53 conformation at 32.5 degrees C, but not in the mutant p53 form at 37 degrees C. However, there was no change in protein expression of FADD, FAP-1, Bcl-2, or Bax at 32.5 or 37 degrees C. Assays for apoptosis demonstrated that anti-Fas antibody CH-11 and FasL induced apoptosis only in cells that overexpress p53 mutant 143Ala at 32.5 degrees C with the wild-type p53 form. Both caspase-3 and caspase-8 activities were increased by anti-Fas antibody CH-11 only in cells at 32.5 degrees C with wild-type p53. Our results demonstrated that Fas-mediated apoptosis in H1299 and PC-3 cells expressing p53 mutant 143Ala occurred only with the wild-type p53 phenotype. These results support the hypothesis that Fas-mediated apoptosis is dependent, at least partially, on the presence of a functional wild-type p53 state. This model may be a useful tool for dissecting the specific interactions between wild-type p53 and the Fas signal transduction pathway in human cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670900

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Standard mutation nomenclature in molecular diagnostics: practical and educational challenges.

Authors:  Shuji Ogino; Margaret L Gulley; Johan T den Dunnen; Robert B Wilson
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

2.  Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.

Authors:  Sudha Neelam; Jessamee Mellon; Amber Wilkerson; Jerry Y Niederkorn
Journal:  Melanoma Res       Date:  2019-08       Impact factor: 3.599

3.  p75NTR is mainly responsible for Aβ toxicity but not for its internalization: a primary study.

Authors:  Huanling Yu; Miao Yang; Yanjiang Wang; Rong Xiao; Xin-Fu Zhou
Journal:  Neurol Sci       Date:  2011-12-20       Impact factor: 3.307

4.  Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships.

Authors:  Xiantao Wang; Anthony J Di Pasqua; Sudha Govind; Erin McCracken; Charles Hong; Lixin Mi; Yuehua Mao; Jessie Yu-Chieh Wu; York Tomita; Jordan C Woodrick; Robert L Fine; Fung-Lung Chung
Journal:  J Med Chem       Date:  2011-01-11       Impact factor: 7.446

5.  Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

Authors:  Andrew M Roberts; Ian R Watson; Andrew J Evans; David A Foster; Meredith S Irwin; Michael Ohh
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

6.  Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus.

Authors:  Kazuhiko Kurozumi; Takashi Tamiya; Yasuhiro Ono; Shinji Otsuka; Hirokazu Kambara; Yoshiaki Adachi; Tomotsugu Ichikawa; Hirofumi Hamada; Takashi Ohmoto
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

7.  Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.

Authors:  Angela Coxon; Beth Ziegler; Stephen Kaufman; Man Xu; Hongyu Wang; Dawn Weishuhn; Joanna Schmidt; Heather Sweet; Charlie Starnes; Douglas Saffran; Anthony Polverino
Journal:  Mol Cancer       Date:  2012-09-19       Impact factor: 27.401

8.  Testing gene set enrichment for subset of genes: Sub-GSE.

Authors:  Xiting Yan; Fengzhu Sun
Journal:  BMC Bioinformatics       Date:  2008-09-02       Impact factor: 3.169

9.  Chemosensitivity assay in mice prostate tumor: Preliminary report of flow cytometry, DNA fragmentation, ion ratiometric methods of anti-neoplastic drug monitoring.

Authors:  Rakesh Sharma; Richard Kline
Journal:  Cancer Cell Int       Date:  2004-03-19       Impact factor: 5.722

10.  The extracellular matrix, p53 and estrogen compete to regulate cell-surface Fas/Apo-1 suicide receptor expression in proliferating embryonic cerebral cortical precursors, and reciprocally, Fas-ligand modifies estrogen control of cell-cycle proteins.

Authors:  Zulfiqar F Cheema; Daniel R Santillano; Stephen B Wade; Joseph M Newman; Rajesh C Miranda
Journal:  BMC Neurosci       Date:  2004-03-23       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.